NCT05735639View on ClinicalTrials.gov

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

PHASE4RecruitingINTERVENTIONAL
Enrollment

6,660

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Venous ThromboembolismVaricose Veins
Interventions
DRUG

Dalteparin Sodium

Low molecular weight heparin

DRUG

Tinzaparin Sodium

Low molecular weight heparin

DRUG

Enoxaparin Sodium

Low molecular weight heparin

DRUG

Rivaroxaban

Direct oral anticoagulant

DRUG

Apixaban

Direct oral anticoagulant

DRUG

Dabigatran Etexilate

Direct oral anticoagulant

Trial Locations (1)

W6 8RF

RECRUITING

Imperial College Hospital NHS Foundation Trust, London

All Listed Sponsors
lead

Imperial College London

OTHER